Comparing Remimazolam and Propofol for Sedation During Fractional Ablative CO2 Laser Treatment of Burn Scars

What this Trial Is About

This research evaluates monitored anesthetic care using remimazolam versus propofol during fractional ablative CO2 laser therapy for burn scars. The study aims to compare the incidence of respiratory depression, defined by the need for advanced airway support or slow breathing rate, in patients undergoing laser treatment for burn scars and hypertrophic scarring. It is a randomized, single-blind, crossover trial where each participant receives both drugs in separate sessions. Participants are randomly assigned to receive either remimazolam or propofol for sedation during their first laser therapy session, followed by the alternate drug 4 to 6 weeks later in their second session. Remimazolam is given as a 0.075 mgkg dose with a maximum of 5 mg, while propofol is administered as a 0.8 mgkg intravenous bolus. This crossover approach allows direct comparison of the effects of these sedatives during outpatient laser procedures. During the study, participants will be monitored for respiratory depression, sedation onset and recovery times, changes in heart function, and overall satisfaction with anesthesia. Researchers will track outcomes up to 24 hours after each procedure, including pain felt during sedation injection. The study involves two outpatient laser sessions spaced several weeks apart, with assessments conducted throughout to ensure safety and collect detailed sedation data.

Remimazolam vs Propofol in Laser Burn Cases